Evidence map›Paper›PMID 42650864›Full record

ArticleBiomolecules2026

Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in

Rongjie Fu, Yalong Wang, Ishita Rehman, Ella Bedford, Sana Sharif, Nghi D Nguyen, Reid T Powell, Andrew Adams, Weijun Liu, Shuyue Wang and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Rongjie FuDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Yalong WangDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0002-9557-9101
Ishita RehmanDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0001-6716-8287
Ella BedfordDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Sana SharifDepartment of Pharmacological and Pharmaceutical Sciences, The University of Houston College of Pharmacy, Houston, TX 77204, USA.ORCID 0009-0004-9886-9130
Nghi D NguyenTexas A&M Health Center for Translational Cancer Research, Houston, TX 77030, USA.ORCID 0000-0001-9379-5401
Reid T PowellTexas A&M Health Center for Translational Cancer Research, Houston, TX 77030, USA.
Andrew AdamsDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Weijun LiuDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0002-4426-6148
Shuyue WangDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Wei HeDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Yue LuDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Bin LiuDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Pooja Anil ShahDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-5445-0443
Jordi Rodon AhnertDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Taiping ChenDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0002-2524-6440
Weiyi PengDepartment of Biology and Biochemistry, University of Houston, Houston, TX 77004, USA.
Clifford C StephanTexas A&M Health Center for Translational Cancer Research, Houston, TX 77030, USA.ORCID 0000-0003-0657-6484
Xinli LiuDepartment of Pharmacological and Pharmaceutical Sciences, The University of Houston College of Pharmacy, Houston, TX 77204, USA.ORCID 0000-0002-1680-1561
Mark T BedfordDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Han XuDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0002-8654-461X

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kathrin Milbury · 1985 to 2026
$290.8M
Computational approaches for protein functional analysis using CRISPR screensR35GM137927 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI XU, HAN · 2020 to 2024
$2.0M
Exploratory studies of cellular resistance to MTA-cooperative PRMT5 inhibitors in MTAP-loss tumors.R21CA296234 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AHNERT, JORDI RODON, BEDFORD, MARK T. · 2025 to 2025
$420k
American Cancer Society RSG-23-1155993-01-MMCancer Prevention and Research Institute of Texas RP200668Cancer Prevention and Research Institute of Texas RP250505NCI NIH HHS P30 CA016672NCI NIH HHS R21 CA296234NIGMS NIH HHS R35 GM137927NIH HHS 1R21CA296234-02NIH HHS 1R35GM137927-05The University of Texas MD Anderson Cancer Center P30 CA016672United States Department of Defense ME220215
6 · The paper itself

Abstract

Protein arginine methyltransferase 5 (PRMT5) is a synthetic lethal target in methylthioadenosine phosphorylase-deleted (

Indexed as

Carcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmLung NeoplasmsProtein-Arginine N-MethyltransferasesProtein Kinase InhibitorsPurine-Nucleoside PhosphorylaseCell Line, TumorHumans5'-methylthioadenosine phosphorylasePRMT5 protein, humanProtein-Arginine N-MethyltransferasesProtein Kinase InhibitorsPurine-Nucleoside Phosphorylaseacquired resistanceMAPK signalingMEK inhibitionMTA-cooperative PRMT5 inhibitorMTAP-nullPRMT5

Identifiers

PMID42650864
PMCPMC13510389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.